NERV - Rasio kapitalisasi pasar marang pendapatan Minerva Neurosciences Corp
Investor caution following FDA claims has pressured quotes, as illustrated by the P/S market multiple. The current level of reflects the valuation of Minerva Neurosciences (NERV), a business developing tools for the social adaptation of schizophrenia patients. The stability of Minerva Neurosciences (NERV) is based on patents for the therapy of sleep disorders and chronic psychoses, which ensure endless demand for its products.
Rincian metrik lan analitis perusahaan Minerva Neurosciences Corp (NERV)
- nilai saham lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Minerva Neurosciences|NERV - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Minerva|NERV - Utang perusahaan|Utang-utang marang nilai buku Minerva Neurosciences Corp|NERV - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Minerva Neurosciences|Indikator likuiditas cepet minervaneurosciences.com
- indikator pendapatan resik lan kelipatan nilai:
NERV - Bathi resik|Prakiraan bathi perusahaan Minerva Neurosciences|NERV - Pangali P/E|Rasio prakiraan rega marang bathi Minerva Neurosciences Inc|NERV - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Minerva Neurosciences Corp|NERV - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Minerva Neurosciences|NERV - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan minervaneurosciences.com|NERV - Wutah bathi saben saham ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Minerva Neurosciences
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:NERV - minervaneurosciences.com
Stable demand for schizophrenia treatments provides Minerva Neurosciences (NERV) with high macroeconomic resilience. By analyzing the price-to-sales multiple, an investor compares current market capitalization with the actual volume of generated revenue. This ratio determines the cost of each dollar of sales, making it possible to distinguish fundamental growth from speculative overheating. Such a valuation confirms the investment attractiveness of a non-cyclical biotech company whose revenues remain independent of market conditions.
Pesaing Minerva Neurosciences
Multiplikator P/S biogen.com (BIIB)|Neurocrine Biosciences, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RGC|AXSM - Rasio rega marang pendapatan|ACAD (ACADIA Corp) - Rasio kapitalisasi marang pendapatan|XENE: Multiplikator P/S|Rega marang dodolan vikingtherapeutics.com (VKTX)|Kapitalisasi marang pendapatan SUPN|Multiplikator P/S Catalyst Pharma|Rasio rega marang pendapatan Denali Therapeutics Inc (DNLI)|HRMY (Harmony Corp) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Biohaven Ltd. BHVN|amylyx.com (AMLX) - Rega marang dodolan|TRVI - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Praxis Precision Medicines Inc PRAX|AVXL: Multiplikator P/S|Kapitalisasi marang pendapatan CeriBell EEG|PRTA (Prothena Biosciences) - Multiplikator P/S|Alector Therapeutics (ALEC) - Koefisien rega marang pendapatan|Multiplikator P/S ANNX|OMER - Rega marang dodolan|Rasio rega marang pendapatan Neurogene Corp NGNE|ACIU: Rasio kapitalisasi marang pendapatan|Voyager Therapeutics - Multiplikator P/S|neumoratx.com (NMRA) - Kapitalisasi marang pendapatan|SCLX: Multiplikator P/S|Rega marang dodolan Tevogen Bio Holdings Inc. (TVGN)|Rasio rega marang pendapatan Alpha Cognition Inc|Cognition Therapeutics Inc. (CGTX) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Inhibikase Therapeutics (IKT)|cassavasciences.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Rega marang dodolan|VTGN - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OVID (Ovid Therapeutics Inc.)|ABOS (Acumen Pharmaceuticals) - Kapitalisasi marang pendapatan|CRVO (cervomed.com) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Alterity Therapeutics Ltd.|Rasio kapitalisasi marang pendapatan CLNN (Clene Nanomedicine)|Multiplikator P/S PEPG|JUNS - Rega marang dodolan|Relmada Therapeutics - Kapitalisasi marang pendapatan|Multiplikator P/S annovisbio.com ANVS|GRCE - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan AIFF (Firefly Neuroscience, Inc.)|anewmeds.com (KLTO) - Rasio rega marang pendapatan|Rega marang dodolan NeuroSense Therapeutics Ltd. (NRSN)|Rasio rega marang pendapatan Reviva Pharmaceuticals|Kapitalisasi marang pendapatan MetaVia, Inc. (MTVA)|Multiplikator P/S NRXS|Koefisien rega marang pendapatan heliusmedical.com|Rasio rega marang pendapatan Passage Bio PASG|NEUP: Rasio kapitalisasi marang pendapatan|Athira Pharma, Inc. - Multiplikator P/S|Rega marang dodolan addextherapeutics.com|alzamend.com (ALZN) - Rasio rega marang pendapatan|Cyclerion Therapeutics, Inc. - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan PTIX|Rasio rega marang pendapatan KTTA|Multiplikator P/S CRGT|Multiplikator P/S avenuetx.com (ATXI)|BrainStorm Cell Therapeutics - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CARA|CHRO - Rasio rega marang pendapatan|ELYM (Eliem Therapeutics) - Rasio kapitalisasi marang pendapatan|ITCI: Multiplikator P/S|Rega marang dodolan longboardpharma.com (LBPH)|Kapitalisasi marang pendapatan MRNS|Multiplikator P/S NKGen Biotech Inc|Rasio rega marang pendapatan NeuroBo (NRBO)|SAGE (Sage Therapeutics Inc) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Synaptogenix, Inc. SNPX|trevena.com (TRVN) - Rega marang dodolan|VIGL - Rasio rega marang pendapatan|Koefisien rega marang pendapatan anewmeds.com WENA|CERE: Multiplikator P/S
